Merus (MRUS) Competitors $43.22 +0.79 (+1.86%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$43.25 +0.03 (+0.07%) As of 04/15/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. RDY, MRNA, ASND, QGEN, VTRS, ROIV, LNTH, RVMD, BBIO, and TGTXShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Viatris (VTRS), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Merus vs. Dr. Reddy's Laboratories Moderna Ascendis Pharma A/S Qiagen Viatris Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma TG Therapeutics Dr. Reddy's Laboratories (NYSE:RDY) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking. Which has better earnings and valuation, RDY or MRUS? Dr. Reddy's Laboratories has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$311.31B0.04$668M$0.6321.19Merus$36.13M80.56-$154.94M-$3.27-12.88 Which has more volatility & risk, RDY or MRUS? Dr. Reddy's Laboratories has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Is RDY or MRUS more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Merus' net margin of -680.61%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% Merus -680.61%-38.89%-31.16% Do analysts recommend RDY or MRUS? Dr. Reddy's Laboratories currently has a consensus target price of $17.00, indicating a potential upside of 27.34%. Merus has a consensus target price of $85.31, indicating a potential upside of 102.49%. Given Merus' stronger consensus rating and higher probable upside, analysts plainly believe Merus is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Merus 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.13 Does the MarketBeat Community believe in RDY or MRUS? Merus received 42 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 67.72% of users gave Merus an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% MerusOutperform Votes36367.72% Underperform Votes17332.28% Does the media refer more to RDY or MRUS? In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 11 articles in the media. Dr. Reddy's Laboratories' average media sentiment score of 1.18 beat Merus' score of 1.16 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Merus 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in RDY or MRUS? 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 4.6% of Merus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryMerus beats Dr. Reddy's Laboratories on 10 of the 18 factors compared between the two stocks. Remove Ads Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.91B$6.31B$5.32B$7.56BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-10.676.7821.7717.81Price / Sales80.56222.80378.2693.59Price / CashN/A65.6738.1534.64Price / Book6.835.826.443.99Net Income-$154.94M$141.86M$3.20B$247.23M7 Day Performance20.75%8.99%6.42%7.24%1 Month Performance-10.55%-12.57%-8.66%-6.26%1 Year Performance2.08%-12.38%10.27%-0.18% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.8298 of 5 stars$43.22+1.9%$85.31+97.4%+4.7%$2.99B$36.13M-10.9437Positive NewsRDYDr. Reddy's Laboratories3.3519 of 5 stars$13.25+0.2%$17.00+28.3%-6.3%$11.06B$311.31B21.1024,800MRNAModerna4.259 of 5 stars$26.80+2.3%$58.70+119.0%-74.7%$10.36B$3.20B-2.893,900Gap DownASNDAscendis Pharma A/S2.3142 of 5 stars$155.50+3.0%$204.64+31.6%+6.0%$9.48B$363.64M-21.901,017News CoveragePositive NewsGap DownQGENQiagen3.483 of 5 stars$42.30+0.8%$47.71+12.8%+7.7%$9.40B$1.98B117.786,030VTRSViatris2.9677 of 5 stars$7.63+1.2%$10.50+37.6%-33.9%$9.11B$14.74B-10.3137,000News CoverageROIVRoivant Sciences2.6317 of 5 stars$10.19+3.3%$17.50+71.7%-7.2%$7.27B$122.59M-67.93860Positive NewsGap DownLNTHLantheus4.3411 of 5 stars$102.13+0.1%$129.43+26.7%+70.6%$6.99B$1.53B16.99700Positive NewsRVMDRevolution Medicines3.8147 of 5 stars$36.47+2.1%$66.67+82.8%+2.2%$6.78B$742,000.00-10.16250Positive NewsBBIOBridgeBio Pharma4.5716 of 5 stars$34.85+2.8%$52.64+51.0%+32.9%$6.63B$221.90M-12.23400Analyst ForecastGap DownTGTXTG Therapeutics3.3148 of 5 stars$38.41+4.6%$40.67+5.9%+177.4%$6.03B$329.00M-384.06290Positive News Remove Ads Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Moderna Competitors Ascendis Pharma A/S Competitors Qiagen Competitors Viatris Competitors Roivant Sciences Competitors Lantheus Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRUS Stock Free MRUS Stock Alerts